{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T08:41:06Z","timestamp":1773218466591,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,11,30]],"date-time":"2016-11-30T00:00:00Z","timestamp":1480464000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Vessels"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s00380-016-0927-6","type":"journal-article","created":{"date-parts":[[2016,11,30]],"date-time":"2016-11-30T03:50:35Z","timestamp":1480477835000},"page":"690-699","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Platelet reactivity and clinical outcomes in patients using CYP3A4-metabolized statins with clopidogrel in percutaneous coronary intervention"],"prefix":"10.1007","volume":"32","author":[{"name":"HOST\u2013ASSURE Investigators","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Sup","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwang Soo","family":"Cha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hye Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-Hyok","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung Hyun","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han Cheol","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taek Jong","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyo Soo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,11,30]]},"reference":[{"issue":"6 Suppl","key":"927_CR1","doi-asserted-by":"crossref","first-page":"199S","DOI":"10.1378\/chest.08-0672","volume":"133","author":"C Patrono","year":"2008","unstructured":"Patrono C, Baigent C, Hirsh J, Roth G, American College of Chest Physicians (2008) Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(6 Suppl):199S\u2013233S","journal-title":"Chest"},{"key":"927_CR2","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1161\/CIRCULATIONAHA.109.192663","volume":"120","author":"FG Kushner","year":"2009","unstructured":"Kushner FG, Hand M, Smith SC Jr, King SB 3rd, Anderson JL, Antman EM, Bailey SR, Bates ER, Blankenship JC, Casey DE Jr, Green LA, Hochman JS, Jacobs AK, Krumholz HM, Morrison DA, Ornato JP, Pearle DL, Peterson ED, Sloan MA, Whitlow PL, Williams DO, American College of Cardiology Foundation, American Heart Association Task Force on Practice Guidelines (2009) 2009 focused updates: ACC\/AHA guidelines for the management of patients with st-elevation myocardial infarction and ACC\/AHA\/SCAI guidelines on percutaneous coronary intervention. Circulation 120:2271\u20132306","journal-title":"Circulation"},{"key":"927_CR3","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1161\/01.CIR.0000072771.11429.83","volume":"107","author":"PA Gurbel","year":"2003","unstructured":"Gurbel PA, Bliden KP, Hiatt BL, O\u2019Connor CM (2003) Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107:2908\u20132913","journal-title":"Circulation"},{"key":"927_CR4","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1016\/j.jacc.2007.07.051","volume":"50","author":"PA Gurbel","year":"2007","unstructured":"Gurbel PA, Becker RC, Mann KG, Steinhubl SR, Michelson AD (2007) Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 50:1822\u20131834","journal-title":"J Am Coll Cardiol"},{"key":"927_CR5","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/j.ehj.2004.07.036","volume":"25","author":"DJ Angiolillo","year":"2004","unstructured":"Angiolillo DJ, Fern\u00e1ndez-Ortiz A, Bernardo E, Ram\u00edrez C, Sabat\u00e9 M, Ba\u00f1uelos C, Hern\u00e1ndez-Antol\u00edn R, Escaned J, Moreno R, Alfonso F, Macaya C (2004) High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. Eur Heart J 25:1903\u20131910","journal-title":"Eur Heart J"},{"key":"927_CR6","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1124\/dmd.109.029132","volume":"38","author":"M Kazui","year":"2010","unstructured":"Kazui M, Nishiya Y, Ishizuka T, Hagihara K, Farid NA, Okazaki O, Ikeda T, Kurihara A (2010) Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 38:92\u201399","journal-title":"Drug Metab Dispos"},{"key":"927_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.carrev.2010.11.001","volume":"12","author":"MJ Price","year":"2011","unstructured":"Price MJ, Tantry US, Gurbel PA (2011) The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors. Rev Cardiovasc Med 12:1\u201312","journal-title":"Rev Cardiovasc Med"},{"key":"927_CR8","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s00380-011-0134-4","volume":"27","author":"M Arima","year":"2012","unstructured":"Arima M, Matsuda A, Nitta M, Yoshida K, Shimizu M (2012) A case of subacute thrombosis associated with clopidogrel resistance after implantation of a zotarolimus-eluting stent. Heart Vessels 27:106\u2013109","journal-title":"Heart Vessels"},{"key":"927_CR9","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jcin.2010.12.009","volume":"4","author":"US Tantry","year":"2011","unstructured":"Tantry US, Kereiakes DJ, Gurbel PA (2011) Clopidogrel and proton pump inhibitors: influence of pharmacological interactions on clinical outcomes and mechanistic explanations. JACC Cardiovasc Interv 4:365\u2013380","journal-title":"JACC Cardiovasc Interv"},{"key":"927_CR10","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.2174\/138161206776361354","volume":"12","author":"H Neubauer","year":"2006","unstructured":"Neubauer H, M\u00fcgge A (2006) Thienopyridines and statins: assessing a potential drug-drug interaction. Curr Pharm Des 12:1271\u20131280","journal-title":"Curr Pharm Des"},{"key":"927_CR11","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1161\/01.CIR.0000047060.60595.CC","volume":"107","author":"ER Bates","year":"2003","unstructured":"Bates ER, Lau WC, Angiolillo DJ (2003) Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug\u2013drug interaction. Circulation 107:32\u201337","journal-title":"Circulation"},{"key":"927_CR12","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jacc.2010.11.024","volume":"57","author":"WC Lau","year":"2011","unstructured":"Lau WC, Waskell LA, Watkins PB, Neer CJ, Horowitz K, Hopp AS, Tait AR, Carville DG, Guyer KE, Bates ER (2011) Clopidogrel\u2013drug interactions. J Am Coll Cardiol 57:1251\u20131263","journal-title":"J Am Coll Cardiol"},{"key":"927_CR13","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1161\/CIRCULATIONAHA.108.812636","volume":"119","author":"R Marcucci","year":"2009","unstructured":"Marcucci R, Gori AM, Paniccia R, Giusti B, Valente S, Giglioli C, Buonamici P, Antoniucci D, Abbate R, Gensini GF (2009) Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 119:237\u2013242","journal-title":"Circulation"},{"issue":"5","key":"927_CR14","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","volume":"11","author":"JM Robins","year":"2000","unstructured":"Robins JM, Hern\u00e1n MA, Brumback B (2000) Marginal structural models and causal inference in epidemiology. Epidemiology 11(5):550\u2013560","journal-title":"Epidemiology"},{"key":"927_CR15","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1527-3466.2007.00027.x","volume":"25","author":"JA Jakubowski","year":"2007","unstructured":"Jakubowski JA, Winters KJ, Naganuma H, Wallentin L (2007) Prasugrel: A novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. Cardiovasc Drug Rev 25:357\u2013374","journal-title":"Cardiovasc Drug Rev"},{"key":"927_CR16","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.jcin.2013.06.014","volume":"6","author":"O Ojeifo","year":"2013","unstructured":"Ojeifo O, Wiviott SD, Antman EM, Murphy SA, Udell JA, Bates ER, Mega JL, Sabatine MS, O\u2019Donoghue ML (2013) Concomitant administration of clopidogrel with statins or calcium-channel blockers: Insights from the TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarcti. JACC Cardiovasc Interv 6:1275\u20131281","journal-title":"JACC Cardiovasc Interv"},{"key":"927_CR17","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1161\/01.CIR.0000112378.09325.F9","volume":"109","author":"WC Lau","year":"2004","unstructured":"Lau WC, Gurbel PA, Watkins PB, Neer CJ, Hopp AS, Carville DGM, Guyer KE, Tait AR, Bates ER (2004) Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 109:166\u2013171","journal-title":"Circulation"},{"key":"927_CR18","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1124\/dmd.31.1.53","volume":"31","author":"TA Clarke","year":"2003","unstructured":"Clarke TA, Waskell LA (2003) The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos 31:53\u201359","journal-title":"Drug Metab Dispos"},{"key":"927_CR19","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0002-9149(03)00626-X","volume":"92","author":"H Wienbergen","year":"2003","unstructured":"Wienbergen H, Gitt AK, Schiele R, Juenger C, Heer T, Meisenzahl C, Limbourg P, Bossaller C, Senges J (2003) Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies. Am J Cardiol 92:285\u2013288","journal-title":"Am J Cardiol"},{"key":"927_CR20","doi-asserted-by":"crossref","first-page":"A50","DOI":"10.1016\/S0735-1097(04)90212-4","volume":"43","author":"J Brophy","year":"2004","unstructured":"Brophy J, Costa V, Babapulle M (2004) A pharmaco-epidemiological study of the interaction between atorvastatin and clopidogrel following percutaneous coronary interventions. J Am Coll Cardiol 43:A50","journal-title":"J Am Coll Cardiol"},{"key":"927_CR21","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1161\/01.CIR.0000088780.57432.43","volume":"108","author":"J Saw","year":"2003","unstructured":"Saw J, Steinhubl SR, Berger PB, Kereiakes DJ, Serebruany VL, Brennan D, Topol EJ (2003) Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation 108:921\u2013924","journal-title":"Circulation"},{"key":"927_CR22","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s00380-012-0248-3","volume":"28","author":"Atsuko Nakayama","year":"2013","unstructured":"Nakayama Atsuko, Morita Hiroyuki, Ando Jiro, Fujita Hideo, Ohtsu Hiroshi, Nagai Ryozo (2013) Adverse cardiovascular outcomes associated with concurrent use of clopidogrel or ticlopidine and proton-pump inhibitors in patients undergoing percutaneous coronary intervention. Heart Vessels 28:292\u2013300","journal-title":"Heart Vessels"},{"key":"927_CR23","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1093\/eurheartj\/ehn046","volume":"29","author":"MJ Price","year":"2008","unstructured":"Price MJ, Endemann S, Gollapudi RR, Valencia R, Stinis CT, Levisay JP, Ernst A, Sawhney NS, Schatz RA, Teirstein PS (2008) Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 29:992\u20131000","journal-title":"Eur Heart J"},{"key":"927_CR24","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S0140-6736(13)61170-8","volume":"382","author":"GW Stone","year":"2013","unstructured":"Stone GW, Witzenbichler B, Weisz G, Rinaldi MJ, Neumann F-J, Metzger DC, Henry TD, Cox DA, Duffy PL, Mazzaferri E, Gurbel PA, Xu K, Parise H, Kirtane AJ, Brodie BR, Mehran R, Stuckey TD (2013) Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet 382:614\u2013623","journal-title":"Lancet"},{"key":"927_CR25","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.jcin.2013.06.010","volume":"6","author":"C Viviani Anselmi","year":"2013","unstructured":"Viviani Anselmi C, Briguori C, Roncarati R, Papa L, Visconti G, Focaccio A, De Micco F, Latronico MV, Pagnotta P, Condorelli G (2013) Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease. JACC Cardiovasc Interv 6:1166\u20131175","journal-title":"JACC Cardiovasc Interv"}],"container-title":["Heart and Vessels"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00380-016-0927-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-016-0927-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-016-0927-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T00:50:08Z","timestamp":1498351808000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00380-016-0927-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,30]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["927"],"URL":"https:\/\/doi.org\/10.1007\/s00380-016-0927-6","relation":{},"ISSN":["0910-8327","1615-2573"],"issn-type":[{"value":"0910-8327","type":"print"},{"value":"1615-2573","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,30]]}}}